GGrantIndex
Sort

39,280 grants matching leukemia

Cancer In the Jerusalem Perinatal Study

$604,299
Columbia University Health Sciences · R01 · FY2004 · CA

Administrative and Informatics

$604,294
Thomas J. Kipps · University Of California, San Diego · P01 · FY2014 · CA

EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES

$604,169
University Of Wisconsin Madison · U10 · FY2004 · CA

Development Of P2Y Receptor Ligands

$604,070
Kenneth Alan Jacobson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2018 · DK

Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic Leukemia

$604,026
Kara Lynn Davis · Stanford University · R01 · FY2022 · CA

Project 4: Secondary Cancers Among NF1 Cancer Survivors

$603,962
Jean Nakamura · Indiana University Indianapolis · U54 · FY2015 · CA

Combination Therapy in B-Chronic Lymphocytic Leukemia

$603,916
Neil E Kay · Mayo Clinic Rochester · R01 · FY2010 · CA

Predicting clinical outcome in individuals with small CLL B cell clones

$603,908
Neil E Kay · Mayo Clinic Rochester · R01 · FY2018 · CA

The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute MyelogenousLeukemia

$603,874
Shujun Liu · Case Western Reserve University · R01 · FY2024 · CA

Pediatric Oncology Clinical Research Training Program

$603,847
Baylor College Of Medicine · K12 · FY2003 · CA

Clinical Trial of Ceramide nanoLiposomes in AML

$603,354
Mark Kester · University Of Virginia · P01 · FY2020 · CA

Targeting the PNP - SAMHD1 synthetic-lethal combination in cancer

$603,347
Vern L. Schramm · Albert Einstein College Of Medicine · R01 · FY2024 · CA

Targeting the PNP - SAMHD1 synthetic-lethal combination in cancer

$603,347
Vern L. Schramm · Albert Einstein College Of Medicine · R01 · FY2025 · CA

Validation of prognostic and pathway signatures in lethal prostate cancer

$603,342
Phillip G Febbo · University Of California, San Francisco · U01 · FY2011 · CA

Development of a Porcine Model of Ataxia-Telangiectasia

$603,232
Christopher Rogers · Exemplar Genetics, Llc · R44 · FY2012 · NS

Phenotype-Genotype Associations with Symptoms During Childhood Leukemia Treatment

$603,111
Marilyn J Hockenberry · Duke University · R01 · FY2016 · CA

Molecular Epidemiology of NHL and CLL

$603,041
James R Cerhan · Mayo Clinic Rochester · R01 · FY2007 · CA

Development of novel selective Rac inhibitors for refractory leukemias

$603,034
David A Williams · Boston Children'S Hospital · R01 · FY2017 · CA

Regulation of the Fanconi Anemia Pathway by Ubiquitination

$603,012
Alan David D'andrea · Dana-Farber Cancer Inst · R01 · FY2011 · DK

Targeting IRE-1a/XBP-1 Axis for Control of Chronic GVHD and Leukemia Relapse

$602,961
Xue-Zhong Yu · Medical University Of South Carolina · R01 · FY2018 · HL

Regulation of T cell development by HDAC3

$602,939
Virginia Smith Shapiro · Mayo Clinic Rochester · R56 · FY2017 · AI

An Academic-Industry Partnership to Advance Functional Genomics for Personalized Oncology.

$602,872
Christopher J Kemp · Fred Hutchinson Cancer Research Center · R01 · FY2020 · CA

Promoting Treatment Adherence in Adolescent Leukemia

$602,850
Dennis D Drotar · Cincinnati Childrens Hosp Med Ctr · R01 · FY2012 · CA

Clonal hematopoiesis, mild cognitive impairment and kidney function decline

$602,674
Michel Benjamin Chonchol · University Of Colorado Denver · R01 · FY2023 · AG

Predictive Markers in Metastatic Renal Cancer

$602,629
Phillip G Febbo · University Of California, San Francisco · R01 · FY2011 · CA